

International
8th Symposium on

URO ONCO LOGY

20
25

AWARDED
WITH 12 CME-
POINTS

12. - 13. DEC. 2025

Maritim Hotel Cologne

Simultaneous translation german/english | hybrid

www.isuo.eu

WELCOME

Dear Colleagues and Friends,

It is our pleasure to invite you to the 8th International Symposium on the management of urogenital malignancies to be held from December 12 - 13, 2025 in Cologne, Germany.

This international meeting has been well established over recent years and it attracted more than 250 participants from 8 different nations.

It is the purpose of our scientific meeting to provide you with information on the latest developments in uro-oncology of 2025 with regard to diagnosis, conservative and surgical treatment of genitourinary malignancies. As in recent years, interdisciplinary case discussions, Pro- and Con debates, state-of-the-art lectures and semi-live videos will be presented by well-known national and international speakers.

We have selected all those innovations around uro-oncological surgery, radiation therapy and system treatment, which most probably will have the most pronounced effects on the management of our patients and which should be introduced in daily clinical routine immediately.

The symposium is organized as a hybrid meeting with simultaneous translation so that no information will get lost and so that all of you can participate in the interactive discussions. Later on you might follow the presentations on demand.

We are looking forward to welcoming you in person and we are looking forward to fruitful discussions in the surrounding and stimulating atmosphere of Cologne at Christmas time.

We remain with warmest regards, Sincerely yours,

Prof. Dr. med. Dr. h.c.

Axel Heidenreich

*Director of the Department of Urology,
Uro-Oncology, and Special Urological
and Robot-Assisted Surgery,
University Hospital Cologne*

Prof. Dr. med.

Martin Schostak

*Medical Director
LOGICURO Berlin*



GENERAL INFORMATION

Organizer
Intercom Dresden GmbH | Zellescher Weg 3 | 01069 Dresden

in cooperation with the scientific direction of
Prof. Dr. med. Dr. h.c Axel Heidenreich
Director of the Department of Urology, Uro-Oncology, and Special Urological and Robot-Assisted Surgery, University Hospital Cologne

Prof. Dr. med. Martin Schostak
Medical Director, Logicro Berlin

Event Location
Maritim Hotel Cologne | Heumarkt 20 | 50667 Cologne

Participation Fee		
Attendance at the event*	early bird	regular
		from 15.11.2025
Specialist physician	285,00 €	305,00 €
Junior physician	160,00 €	190,00 €
Student	Free of charge (with verification)	
University hospital employee (Urology) Cologne	Free of charge (with verification)	

Virtual*	early bird	regular
		from 15.11.2025
Specialist physician	175,00 €	205,00 €
Junior physician	105,00€	125,00 €
Student	Free of charge (with verification)	
University hospital employee (Urology) Cologne	Free of charge (with verification)	

Registration
www.isuo.eu/2025/registration

Certification:
The symposium has been awarded with 12 training points category A by the North Rhine Medical Association.

Organisation industrial exhibition
Intercom Dresden GmbH | Christian Nitzsche, Katharina Henze
Zellescher Weg 3, 01069 Dresden | **Phone:** +49 351 320173 -30/-70 |
E-Mail: isuo@intercom-kongresse.de

* Intercom Dresden GmbH is the organiser. All registration fees are per person, including 19% VAT, collected in the name and for the account of Intercom Dresden GmbH, Zellescher Weg 3, 01069 Dresden, Germany, UST-ID Nr.: DE 186530195 | This event is supported by industry sponsorship. This sponsorship will be used exclusively for the financing of the following conference services: Participant administration, organisational costs, speaker’s fee, printed material, rental costs for event rooms, rental costs for presentation technology as well as for appropriate refreshments during breaks.

MAIN TOPICS

Prostate Cancer:
active surveillance, innovative treatment options in organ confined and locally advanced prostate cancer, radionuclid and targeted treatment options

Urothelial Cancer:
immuno-oncological treatment concepts, role of radical cystectomy in the management of muscle invasive disease, SEMI LIVE surgery on urinary diversions, management of upper urinary tract cancer

Renal Cancer:
organ preserving surgical and non-surgical treatment options, cytoreductive nephrectomy, retroperitoneal lymph node dissection

Testis Cancer/Penile Cancer:
state-of-the Art guidelines recommended treatment options

8:45	Welcome <i>Moderation: A. Heidenreich, Cologne, GER</i>
08:50	Prostate Cancer – early detection, screening and diagnosis <i>Moderation: A. Heidenreich, Cologne, GER M. Schostak, Berlin, GER</i>
08:50	Individualized early detection: PROBASE <i>R. Al-Monajjed, Düsseldorf, GER</i>
09:03	Prostate cancer screening with PSA, kallikrein panel and MRI: the ProScreen trial <i>A. Auvinen, Tampere, FIN</i>
09:16	Hot Topic: Optimum <i>M. Schostak, Berlin, GER</i>

09:42	Urothelial carcinoma 1 – non-muscle invasive deintensification of follow-up and active treatment <i>Moderation: S. Lerner, Houston, USA F. Roghmann, Herne, GER</i>
09:42	Case Presentation: pTa, low grade <i>L. Bohn, Cologne, GER</i>
09:44	TUR-B remains standard management <i>R. Schiavina, IT</i>
09:54	Active Surveillance ± outpatient fulguration <i>M. Babjuk, Prague, CZ</i>
10:04	Role of urinary markers <i>T. Ecke, Bad Saarow, GER</i>
10:14	Discussion

10:24	Treatment strategies for BCG-refractory TCC: Pro and Contra
10:24	Case presentation <i>O. Steenbook, Cologne, GER</i>
10:26	Radical cystectomy remains as best option <i>S. Roghmann, Herne, GER</i>
10:36	Intravesical salvage is an an good option <i>M. Babjuk, Prag, CZ</i>
10:46	Discussion

10:50 Coffee Break

11:25	PCA – intermediate risk favourable: what to do? <i>Moderation: A. Blana, Fürth, GER A. Auvinen, Tampere, FIN</i>
11:25	Case Presentation <i>R. Weiten, Cologne, GER</i>
11:26	Active Surveillance <i>M. Schostak, Berlin, GER</i>
11:37	nsRLAP <i>J. Karnes, Rochester, USA</i>
11:47	Extreme hypofractionation: the gold standard in modern radiotherapy? <i>E. Fokas, Cologne, GER</i>
11:57	HIFU <i>A. Blana, Fürth, GER</i>
12:07	Discussion

12:15 **Satellite Symposium 1: Johnson & Johnson**

13:00 Lunch Break

13:55	Urothelial carcinoma 2 – locally advanced/metastasised <i>Moderation: M. Babjuk, Prag, CZ S. Roghmann, Herne, GER</i>
13:55	Case Presentation: Urothelial carcinoma of the bladder cT3cN1cM1a, 6 cycles ddMVAC => ycT2cN0cM0 <i>C. Rieger, Cologne, GER</i>
13:57	It is still a palliative treatment <i>L. Caruscelli, Munich, GER</i>
14:07	Cytoreductive radical cystectomy + pLAD + RPLA <i>S. Lerner, Houston, USA</i>
14:17	Cytoreductive radiation therapy is the best alternative <i>U. Ganswindt, Innsbruck, AT</i>
14:27	Discussion

14:35 **Satellite Symposium 2: AstraZeneca GmbH**

15:20	Urothelial carcinoma 3 – Urinary bladder muscle-invasive, organ-confined <i>Moderation: C. Rieger, Cologne, GER H. Kübler, Würzburg, GER</i>
15:20	Neoadjuvant therapy: which regime to take? <i>A. Lorch, Zurich, CH</i>
15:35	Complete Response – cured? <i>S. Lerner, Houston, USA</i>
15:50	Discussion

16:00 Coffee Break

16:35	Urothelial carcinoma 4: low volume de novo PCA <i>Moderation: A. Blana, Fürth, GER N.N.</i>
16:35	Case Presentation <i>J. Heidenreich, Cologne, GER</i>
16:36	System therapy does everything <i>S. Zschäbitz, Heidelberg, GER</i>
16:47	Surgical eradication is also required <i>J. Karnes, Rochester, USA</i>
16:57	Only radiotherapy is successful <i>U. Ganswindt, Innsbruck, AT</i>
17:07	Discussion
17:15	Special Lecture <i>Moderation: A. Heidenreich, Cologne, GER</i> Correct interpretation of clinical trials for the benefit of our patients <i>K. Binder, Munich, GER</i>
17:45	Semi-Live <i>Moderation: D. Pfister, Cologne, GER J. Karnes, Rochester, USA</i>
17:45	RPLA in germ cell tumors <i>A. Heidenreich, Cologne, GER</i>
17:57	Caval thrombus in renal cell carcinoma <i>A. Haferkamp, Mainz, GER</i>
18:09	Radio-guided sentinel lymphadenectomy in prostate cancer <i>L. Fumado, Barcelona, ESP</i>
18:21	Sentinel lymph node dissection in penile cancer <i>F. Wawroschek, Oldenbrug, GER</i>
18:33	Discussion
18:45	End of Day 1

08:30	Welcome <i>Moderation: A. Heidenreich, Cologne, GER</i>
08:30	Renal Cancer – management of small renal masses <i>Moderation: A. Heidenreich, Köln, GER N.N.</i>
08:30	Case Presentation <i>D. Klußmann, Köln, GER</i>
08:32	Active surveillance only with a biopsy <i>A. Volpe, Novara, IT</i>
08:42	Organsparing surgery is the safest approach <i>N. Harke, Hannover, GER</i>
08:52	Molecular imaging enables individualized treatment <i>J. Bedke, Stuttgart, GER</i>
09:02	Discussion
09:10	Satellite Symposium 3: Ipsen Pharma GmbH
09:55	Coffee Break
10:25	Hot topics testis cancer <i>Moderation: P. Paffenholz, Cologne, GER S. Zschäbitz, Heidelberg, GER</i>
10:25	New prognostic markers for clinical stage <i>A. Heidenreich, Cologne, GER</i>
10:35	Seminoma, good risk, LDH↑: 3 or 4 x PEB <i>A. Patrikidou, Paris, FRA</i>
10:45	Long-term toxicity of chemo and radiation therapy <i>T. Tandstad, Trondheim, NOR</i>
10:55	Discussion
11:05	Urothelial carcinoma 5: upper urinary tract – Pro und Contra <i>Moderation: S. Lerner, Houston, USA N.N.</i>
11:05	Case Presentation: UTUC renal pelvis cT2cN1HG <i>S. Semko, Cologne, GER</i>
11:07	Neoadjuvant therapy <i>N.N.</i>
11:17	Adjuvant therapy <i>A. Birtle, Preston, UK</i>
11:27	Panel discussion
11:25	UTUC oft the mid urter: pT1HGcN0 ,eGFR < 40 ml/min <i>S. Semko, Cologne, GER</i>
11:37	Radical nephroureterectomy <i>H. Kübler, Würzburg, GER</i>
11:47	Organ preservation <i>D. Pfister, Cologne, GER</i>
11:57	Panel discussion

12:00 Break

12:20 Postate Cancer, mCRPC
Progression following Triple Therapy – what to do?

Moderation: A. Heidenreich, Cologne, GER |
M. Schostak, Berlin, GER

12:20 Case Presentation
E. Nohl, Cologne, GER

12:22 Cabazitaxel is the next step
S. Oudard, Paris, FRA

12:32 ¹⁷⁷Lu-PSMA is treatment of choice
A. Drzezga, Cologne, GER

12:42 Talazoparib + Enzalutamid
S. Zschäbitz, Heidelberg, GER

12:52 Discussion

13:05 Adjourn
M. Schostak, Berlin, GER

SPONSORSHIP AND EXHIBITORS

An important part of this event is the accompanying exhibition, which is centrally integrated into the event format. With catering provided in this area, it will serve as a central meeting point for networking and exchange. We warmly invite you to support and participate the International Symposium on Urological Tumors. There are various opportunities to present your company as part of this event.

We would be pleased to provide you with the appropriate documents.

INTERCOM
DIE VERANSTALTUNGSAGENTUR

Intercom Dresden GmbH
Christian Nitzsche, Katharina Henze
Zellescher Weg 30
01069 Dresden
Phone: +49 351 320 173-30 / -70
Email: ISUO@intercom-kongresse.de

in cooperation with the scientific partners



UNIKLINIK
KÖLN

LOG\$CURO
Prof. Dr. med. Martin Schostak



Center for Integrated Oncology
Aachen Bonn Cologne Duesseldorf